Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOEL S WOLINSKY

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1225227499
CMS profile
191449
Location
WEATHERFORD, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$30.25

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $30.25 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Mallinckrodt Enterprises LLC $30.25 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOEL S WOLINSKY

NPI 1225227499 · CMS profile ID 191449

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

WEATHERFORD, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1225227499?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOEL S WOLINSKY, NPI 1225227499, CMS profile ID 191449. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1225227499?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JOEL S WOLINSKY, NPI 1225227499, CMS profile ID 191449. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1225227499?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JOEL S WOLINSKY, NPI 1225227499, CMS profile ID 191449, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1225227499?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $30.25 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Mallinckrodt Enterprises LLC $30.2505/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704760819 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $30.25 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019
Generated from
OP_DTL_GNRL_PGYR2019_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

This record has limited reported data across the program years shown and is not featured in search indexes. The records below are complete; see the methodology for how featured pages are determined.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2020 Principal investigator $102,060.10 30
PY2019 Principal investigator $337,726.62 208

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

208 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eisai Inc. $1,207.00 12/31/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551817
Principal investigator 1 Eisai Inc. $1,859.00 11/26/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551865
Principal investigator 1 Eisai Inc. $75.00 11/26/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551867
Principal investigator 1 Eisai Inc. $2,496.00 11/26/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551869
Principal investigator 1 Eisai Inc. $2,496.00 11/26/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551871
Principal investigator 1 Eisai Inc. $4,165.00 10/31/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551847
Principal investigator 1 Eisai Inc. $2,360.00 10/31/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551849
Principal investigator 1 Eisai Inc. $4,165.00 10/31/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551851
Principal investigator 1 Eisai Inc. $2,360.00 10/31/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551853
Principal investigator 1 Eisai Inc. $4,165.00 10/31/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551855
Principal investigator 1 Eisai Inc. $2,360.00 10/31/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551857
Principal investigator 1 Eisai Inc. $3,956.00 10/31/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551859
Principal investigator 1 Eisai Inc. $4,165.00 10/31/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551861
Principal investigator 1 Eisai Inc. $2,360.00 10/31/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551863
Principal investigator 1 Eisai Inc. $3,934.00 10/01/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551537
Principal investigator 1 Eisai Inc. $2,005.00 10/01/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551539
Principal investigator 1 Eisai Inc. $2,005.00 10/01/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551541
Principal investigator 1 Eisai Inc. $2,360.00 10/01/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551543
Principal investigator 1 Eisai Inc. $2,360.00 10/01/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551545
Principal investigator 1 Eisai Inc. $1,672.00 08/15/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551547
Principal investigator 1 Eisai Inc. $956.00 08/15/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551549
Principal investigator 1 Eisai Inc. $1,859.00 08/15/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551551
Principal investigator 1 Eisai Inc. $605.00 08/15/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551553
Principal investigator 1 Eisai Inc. $452.00 08/15/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551555
Principal investigator 1 Eisai Inc. $75.00 08/15/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551557
Principal investigator 1 Eisai Inc. $3,840.00 08/15/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551559
Principal investigator 1 Eisai Inc. $3,956.00 07/09/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551561
Principal investigator 1 Eisai Inc. $1,677.00 07/09/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551571
Principal investigator 1 Eisai Inc. $2,731.00 07/09/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551573
Principal investigator 1 Eisai Inc. $1,207.00 07/09/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551575
Principal investigator 1 Eisai Inc. $2,005.00 05/30/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551563
Principal investigator 1 Eisai Inc. $4,178.00 05/30/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551565
Principal investigator 1 Eisai Inc. $2,360.00 05/30/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551567
Principal investigator 1 Eisai Inc. $2,212.00 05/30/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551569
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551577
Principal investigator 1 Eisai Inc. $4,165.00 05/07/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551579
Principal investigator 1 Eisai Inc. $2,360.00 05/07/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551581
Principal investigator 1 Eisai Inc. $3,840.00 05/07/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551583
Principal investigator 1 Eisai Inc. $4,165.00 05/07/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551585
Principal investigator 1 Eisai Inc. $2,360.00 05/07/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551587
Principal investigator 1 Eisai Inc. $3,840.00 05/07/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551589
Principal investigator 1 Eisai Inc. $3,287.00 05/07/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551591
Principal investigator 1 Eisai Inc. $1,875.00 05/07/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551593
Principal investigator 1 Eisai Inc. $956.00 05/07/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551595
Principal investigator 1 Eisai Inc. $1,859.00 05/07/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551597
Principal investigator 1 Eisai Inc. $605.00 05/07/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551599
Principal investigator 1 Eisai Inc. $452.00 05/07/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551601
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551603
Principal investigator 1 Eisai Inc. $1,672.00 05/07/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551605
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551607
Principal investigator 1 Eisai Inc. $1,672.00 05/07/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551609
Principal investigator 1 Eisai Inc. $1,672.00 05/07/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551823
Principal investigator 1 Eisai Inc. $452.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551611
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551613
Principal investigator 1 Eisai Inc. $1,672.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551615
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551617
Principal investigator 1 Eisai Inc. $956.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551619
Principal investigator 1 Eisai Inc. $1,859.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551621
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551623
Principal investigator 1 Eisai Inc. $605.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551625
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551627
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551629
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551631
Principal investigator 1 Eisai Inc. $1,672.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551633
Principal investigator 1 Eisai Inc. $956.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551635
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551637
Principal investigator 1 Eisai Inc. $1,859.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551639
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551641
Principal investigator 1 Eisai Inc. $605.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551643
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551645
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551647
Principal investigator 1 Eisai Inc. $1,677.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551649
Principal investigator 1 Eisai Inc. $1,672.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551651
Principal investigator 1 Eisai Inc. $2,731.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551653
Principal investigator 1 Eisai Inc. $2,360.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551655
Principal investigator 1 Eisai Inc. $3,840.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551657
Principal investigator 1 Eisai Inc. $1,207.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551659
Principal investigator 1 Eisai Inc. $2,360.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551661
Principal investigator 1 Eisai Inc. $3,840.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551663
Principal investigator 1 Eisai Inc. $3,840.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551665
Principal investigator 1 Eisai Inc. $2,360.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551667
Principal investigator 1 Eisai Inc. $3,840.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551669
Principal investigator 1 Eisai Inc. $1,672.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551671
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551673
Principal investigator 1 Eisai Inc. $956.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551675
Principal investigator 1 Eisai Inc. $2,360.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551677
Principal investigator 1 Eisai Inc. $2,360.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551679
Principal investigator 1 Eisai Inc. $3,840.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551681
Principal investigator 1 Eisai Inc. $2,360.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551683
Principal investigator 1 Eisai Inc. $3,840.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551685
Principal investigator 1 Eisai Inc. $1,207.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551687
Principal investigator 1 Eisai Inc. $2,360.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551689
Principal investigator 1 Eisai Inc. $2,360.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551691
Principal investigator 1 Eisai Inc. $3,840.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551693
Principal investigator 1 Eisai Inc. $1,859.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551695
Principal investigator 1 Eisai Inc. $2,360.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551697
Principal investigator 1 Eisai Inc. $3,840.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551699
Principal investigator 1 Eisai Inc. $2,360.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551701
Principal investigator 1 Eisai Inc. $3,840.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551703
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551705
Principal investigator 1 Eisai Inc. $605.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551707
Principal investigator 1 Eisai Inc. $452.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551709
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551711
Principal investigator 1 Eisai Inc. $1,672.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551713
Principal investigator 1 Eisai Inc. $956.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551715
Principal investigator 1 Eisai Inc. $1,859.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551717
Principal investigator 1 Eisai Inc. $956.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551719
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551721
Principal investigator 1 Eisai Inc. $605.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551723
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551725
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551727
Principal investigator 1 Eisai Inc. $1,672.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551729
Principal investigator 1 Eisai Inc. $956.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551731
Principal investigator 1 Eisai Inc. $1,859.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551733
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551735
Principal investigator 1 Eisai Inc. $605.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551737
Principal investigator 1 Eisai Inc. $1,859.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551739
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551741
Principal investigator 1 Eisai Inc. $452.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551743
Principal investigator 1 Eisai Inc. $1,672.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551745
Principal investigator 1 Eisai Inc. $956.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551747
Principal investigator 1 Eisai Inc. $1,859.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551749
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551751
Principal investigator 1 Eisai Inc. $605.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551753
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551755
Principal investigator 1 Eisai Inc. $1,672.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551757
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551759
Principal investigator 1 Eisai Inc. $956.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551761
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551763
Principal investigator 1 Eisai Inc. $605.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551765
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551767
Principal investigator 1 Eisai Inc. $452.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551769
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551771
Principal investigator 1 Eisai Inc. $1,672.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551773
Principal investigator 1 Eisai Inc. $956.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551775
Principal investigator 1 Eisai Inc. $1,859.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551777
Principal investigator 1 Eisai Inc. $605.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551779
Principal investigator 1 Eisai Inc. $605.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551781
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551783
Principal investigator 1 Eisai Inc. $452.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551785
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551787
Principal investigator 1 Eisai Inc. $1,672.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551789
Principal investigator 1 Eisai Inc. $956.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551791
Principal investigator 1 Eisai Inc. $1,859.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551793
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551795
Principal investigator 1 Eisai Inc. $605.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551797
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551799
Principal investigator 1 Eisai Inc. $452.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551801
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551803
Principal investigator 1 Eisai Inc. $1,672.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551805
Principal investigator 1 Eisai Inc. $956.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551807
Principal investigator 1 Eisai Inc. $1,859.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551809
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551811
Principal investigator 1 Eisai Inc. $605.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551813
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551815
Principal investigator 1 Eisai Inc. $452.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551825
Principal investigator 1 Eisai Inc. $452.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551827
Principal investigator 1 Eisai Inc. $2,360.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551829
Principal investigator 1 Eisai Inc. $3,840.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551831
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551833
Principal investigator 1 Eisai Inc. $452.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551835
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551837
Principal investigator 1 Eisai Inc. $1,859.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551839
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551841
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551843
Principal investigator 1 Eisai Inc. $452.00 04/02/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551845
Principal investigator 1 Eisai Inc. $2,286.00 03/12/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551457
Principal investigator 1 Eisai Inc. $27,181.12 03/12/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551499
Principal investigator 1 Eisai Inc. $1,672.00 03/12/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551501
Principal investigator 1 Eisai Inc. $956.00 03/12/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551503
Principal investigator 1 Eisai Inc. $1,672.00 03/12/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551505
Principal investigator 1 Eisai Inc. $75.00 03/12/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551507
Principal investigator 1 Eisai Inc. $4,178.00 03/12/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551509
Principal investigator 1 Eisai Inc. $2,360.00 03/12/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551511
Principal investigator 1 Eisai Inc. $3,840.00 03/12/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551513
Principal investigator 1 Eisai Inc. $1,207.00 03/12/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551515
Principal investigator 1 Eisai Inc. $2,005.00 03/12/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551517
Principal investigator 1 Eisai Inc. $2,360.00 03/12/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551519
Principal investigator 1 Eisai Inc. $3,840.00 03/12/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551521
Principal investigator 1 Eisai Inc. $1,859.00 03/12/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551523
Principal investigator 1 Eisai Inc. $75.00 03/12/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551525
Principal investigator 1 Eisai Inc. $605.00 03/12/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551527
Principal investigator 1 Eisai Inc. $75.00 03/12/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551529
Principal investigator 1 Eisai Inc. $452.00 03/12/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551531
Principal investigator 1 Eisai Inc. $1,672.00 03/12/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551533
Principal investigator 1 Eisai Inc. $75.00 03/12/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551535
Principal investigator 1 Eisai Inc. $285.50 03/12/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551819
Principal investigator 1 Eisai Inc. $75.00 03/12/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551821
Principal investigator 1 Eisai Inc. $1,672.00 01/24/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551483
Principal investigator 1 Eisai Inc. $956.00 01/24/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551485
Principal investigator 1 Eisai Inc. $1,859.00 01/24/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551487
Principal investigator 1 Eisai Inc. $75.00 01/24/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551489
Principal investigator 1 Eisai Inc. $1,672.00 01/24/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551491
Principal investigator 1 Eisai Inc. $75.00 01/24/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551493
Principal investigator 1 Eisai Inc. $2,212.00 01/24/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551495
Principal investigator 1 Eisai Inc. $3,287.00 01/24/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551497
Principal investigator 1 Eisai Inc. $1,672.00 01/03/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551459
Principal investigator 1 Eisai Inc. $956.00 01/03/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551461
Principal investigator 1 Eisai Inc. $3,287.00 01/03/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551463
Principal investigator 1 Eisai Inc. $1,875.00 01/03/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551465
Principal investigator 1 Eisai Inc. $75.00 01/03/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551467
Principal investigator 1 Eisai Inc. $1,859.00 01/03/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551469
Principal investigator 1 Eisai Inc. $605.00 01/03/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551471
Principal investigator 1 Eisai Inc. $75.00 01/03/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551473
Principal investigator 1 Eisai Inc. $452.00 01/03/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551475
Principal investigator 1 Eisai Inc. $75.00 01/03/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551477
Principal investigator 1 Eisai Inc. $2,360.00 01/03/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551479
Principal investigator 1 Eisai Inc. $3,840.00 01/03/2019 Non-covered Recipient Entity
CLINICAL TRIAL NETWORK, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702551481